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A soluble form of the mannose receptor (sMR) has
been found in conditioned medium of primary macro-
phages in vitro and in mouse serum. sMR was released
as a single species, had a smaller size than the cell-
associated form, and accumulated in macrophage-con-
ditioned medium, in a cytokine-regulated manner, to
levels comparable with those found for cell-associated
mannose receptor. Pulse-chase experiments showed
that sMR production in culture occurred by constitutive
cleavage of pre-existing full-length protein. A binding
assay was developed to determine the sugar specificity
of sMR and its ability to interact with pathogens and
particulate antigens (i.e. Candida albicans and zymo-
san). Protease inhibitor studies suggested that sMR was
produced by cleavage of an intact mannose receptor by
a matrix metalloprotease or ADAM metalloprotease. A
role for sMR in the immune response is proposed based
on its binding properties, regulation by cytokines, and
the previous discovery of putative ligands for the cys-
teine-rich domain of the mannose receptor in lymph
nodes and spleen.
The mannose receptor (MR)1 is a type I integral membrane
glycoprotein expressed on many macrophage (MØ) subtypes,
monocyte-derived dendritic cells, and hepatic endothelium (1–
4). MR is the founding member of a family of molecules sharing
the same basic domain structure: an NH2-terminal cysteine-
rich domain; a fibronectin type II domain; and a variable num-
ber of C-type lectin carbohydrate recognition domains (CRDs),
eight in the case of MR, followed by a transmembrane domain
and a COOH-terminal intracellular domain (5–7). The other
members of the family are: (i) the phospholipase A2 receptor,
which contains eight CRDs and is widely distributed (8–10); (ii)
the receptor DEC-205, which contains 10 CRDs and is ex-
pressed mostly by dendritic cells in T-cell areas of secondary
lymphoid organs and by thymic and intestinal epithelia (11–
13); and (iii) a recently described molecule found by its homol-
ogy to the C-type lectin domain of E-selectin (14).
Mannosylated molecules and particles can be endocytosed
and phagocytosed through their interaction with the MR (3, 4,
15–19). The domains likely to be involved in this process are
the CRDs and the transmembrane and the COOH-terminal
intracellular domains. Neither the cysteine-rich domain nor
the fibronectin type II domain seems to be required (18, 20).
MR synthesis and function are regulated by MØ maturation,
lipopolysaccharide (LPS) (3), and cytokines; inhibited by inter-
feron (IFN)-g (6); and up-regulated by IL-4 and -13 (21, 22).
Using as a probe a chimeric protein containing the cysteine-
rich domain of the MR fused to the Fc region of human IgG1
(CR-Fc), we found putative ligand(s) for this domain of the MR
in marginal zone metallophilic and subcapsular sinus MØ in
naive mice and in the germinal centers of immunized mice.
CR-Fc1 cells with dendritic morphology migrated toward the
follicular areas and paracortex of lymph nodes during a sec-
ondary immune response (23). We hypothesized a role for a
soluble form of the MR in the transport of sugar-bearing mol-
ecules and/or particles to sites of humoral immune responses.
In this report, we demonstrate the existence of such a form in
vitro and in vivo. sMR was readily detected in media from
cultured primary MØ and was produced by constitutive cleav-
age of a pre-existing cellular form. A simple and rapid binding
assay was developed to test the sugar specificity of sMR (D-
mannose 5 L-fucose . D-galactose) and its ability to interact
with particulate antigens (Candida albicans and zymosan) in a
carbohydrate-dependent manner. sMR was also detected in
mouse serum. Possible functions for sMR will be discussed.
EXPERIMENTAL PROCEDURES
Animals—Balb/c and C57BL/6 mice were bred at the Dunn School of
Pathology and used at 10–12 weeks of age.
Cytokines, Antibodies, and Reagents—Murine IL-4 was from R&D
Systems (Minneapolis, MN). Murine IFN-g was from Genzyme Diag-
nostics (Cambridge, MA). Rabbit polyclonal antibody against purified
murine mannose receptor (24) was absorbed with thymocytes. Rabbit
polyclonal antibody against the COOH end of the MR was obtained by
immunizing New Zealand White rabbits with the synthetic peptide
NH2-SNLSPGTSDTKDLMGNIEQNEH-COOH (200 mg of peptide per
immunization). LPS, zymosan from Saccharomyces cerevisiae, D-man-
nose, L-fucose, D-galactose, mannan, p-aminophenyl a-D-mannosyl-aga-
rose, and p-aminophenyl a-D-galactosyl-agarose were purchased from
Sigma (Poole, Dorset, UK). Mannose-BSA (Man32-BSA, 32 mol of man-
nose/mol of bovine serum albumin) was purchased from EY Laborato-
ries (San Mateo, CA). The protease inhibitors N-[N-(L-3-trans-carbox-
irane-2-carbonyl)-L-leucyl]-agmatine (E-64, cysteine proteinase
inhibitor), pepstatin (acid proteinase inhibitor), and a2-macroglobulin
(broad spectrum proteinase inhibitor) were from Boehringer Mannheim
(Lewes, UK). The matrix metalloprotease inhibitor BB 2116 was a kind
gift of Dr. Andrew Gearing of British Biotech (Oxford, UK). Peroxidase-
conjugated donkey anti-rabbit IgG was from Chemicon (Harrow, UK).
Protein G-Sepharose was from Amersham Pharmacia Biotech (Upp-
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sala, Sweden). Stock cultures of C. albicans (ATCC 18804) were pre-
pared as described (25).
Macrophage Culture—Bio-Gel-elicited peritoneal cells were collected
by lavage 4 days after intraperitoneal injection of 1 ml of a 1% w/v
suspension of Bio-Gel P100 polyacrylamide beads (Bio-Rad). MØs were
enriched by adherence for 1–2 h in Opti-MEM (Life Technologies, Inc.,
Paisley, UK) supplemented with 10 mM L-glutamine, 50 units/ml pen-
icillin, and 50 mg/ml streptomycin. Cells were cultured in Opti-MEM or
RPMI supplemented with 2% FCS, 10 mM L-glutamine, 50 units/ml
penicillin, and 50 mg/ml streptomycin (RPMI-2% FCS) in the absence or
presence of different cytokines or stimuli.
Detection of MR in Cell Lysates and Supernatants by Western Blot—
Cell supernatants were cleared at 2000 rpm for 5 min in a tabletop
centrifuge and at 100,000 3 g for 30 min, concentrated using Centricon
30 (Amicon, Beverly, MA), and stored at 220 °C. Cells were washed
with phosphate-buffered saline and lysed in the dish with 2% Triton
X-100, 10 mM Tris-HCl, pH 8, 150 mM NaCl, 10 mM NaN3, 10 mM EDTA,
5 mM iodoacetamide, 2 mM phenylmethylsulfonyl fluoride, 1 mg/ml
pepstatin, and 1 mM leupeptin at 4 °C for 1 h, then harvested, and
centrifuged at 2000 rpm for 5 min in a tabletop centrifuge to eliminate
nuclei. Protein concentrations in cell lysates were determined by the
BCA method (Pierce). Corresponding amounts of concentrated condi-
tioned media and cell lysates were electrophoresed in 6% SDS-poly-
acrylamide gels under nonreducing conditions and transferred to nitro-
cellulose using standard methods. Blotted proteins were probed with
rabbit anti-MR antibody and specific bands visualized using peroxi-
dase-conjugated anti-rabbit IgG and enhanced chemiluminescence
(Amersham Pharmacia Biotech, Bucks, UK).
Semiquantitative Ligand Binding Assay—20 ml of concentrated con-
ditioned media from MØ cultured in RPMI-2% FCS containing 10 ng/ml
IL-4 or 10–50 ml of mouse serum were diluted in binding buffer (10 mM
Tris-HCl, pH 7.4, 1 M NaCl, 15 mM CaCl2, and 0.1% Triton X-100) to 400
ml and incubated with 20 ml of p-aminophenyl a-D-mannose-agarose or
p-aminophenyl a-D-galactose-agarose in the absence or presence of dif-
ferent inhibitors for 2–16 h at 4 °C. Agarose beads were collected by
centrifugation and washed 3 times with binding buffer. Bound proteins
were eluted by incubating the beads with nonreducing loading buffer
containing 25 mM EDTA, resolved on a 6% SDS-PAGE, and transferred
to nitrocellulose. sMR was detected as described above. A modified
version of this procedure was used to test the ability of sMR to bind
particulate antigens (C. albicans or zymosan) by substituting the aga-
rose beads with 2 3 107–108 particles/assay.
Detection of Mannose Receptor by Immunoprecipitation—3 3 106
Bio-Gel-elicited MØ were plated in 35-mm dishes and cultured over-
night in Opti-MEM or RPMI-2% FCS in the absence or presence of
cytokines or LPS. For pulse-chase experiments, cells were incubated in
0.5 ml of labeling media (RPMI without L-methionine and L-cysteine, 1
2% dialyzed FCS 1 0.5 mCi/ml Tran35S-label (ICN Biomedicals Ltd.,
Thame, UK)) for 2 h, and either supernatants and cells were processed
immediately for immunoprecipitation or cells were washed in RPMI-2%
FCS containing a 10-fold excess of L-methionine and L-cysteine and
incubated further in 1 ml of the same media for different periods of
time. Cells were washed in phosphate-buffered saline, lysed in 300 ml of
lysis buffer for 1 h at 4 °C, harvested and centrifuged at 2000 rpm for 5
min in a tabletop centrifuge, and cleared at 100,000 3 g for 30 min.
Supernatants were cleared in the same way. 100 ml of cell lysate and
330 ml of supernatant were brought to a final volume of 500 ml with lysis
buffer and precleared for 2 h with 10 ml of protein G-Sepharose (Phar-
macia). After preclearing, lysates and supernatants were incubated
overnight with 2 ml of anti-MR antibody and 10 ml of protein G-Sepha-
rose at 4 °C. After incubation, Sepharose beads were washed 3 times in
10 mM Tris-HCl, pH 8, 500 mM NaCl, 0.5% (w/v) deoxycholate, 0.5%
(v/v) Triton X-100, 0.05% (w/v) SDS; twice in 10 mM Tris-HCl, pH 8, 150
mM NaCl, 0.05% (w/v) SDS; and once in 10 mM Tris-HCl, pH 8, 0.05%
(w/v) SDS. Proteins were eluted in nonreducing loading buffer, resolved
by 6% SDS-PAGE, and visualized by fluorography. In some cases,
immunoprecipitated cMR and sMR were quantified using PhosphorIm-
ager analysis.
RESULTS
A Soluble Form of the Mannose Receptor Is Present in Super-
natants of Murine Primary Macrophages—To examine the pos-
sible existence of a soluble form of the MR, cell lysates and
supernatants from Bio-Gel-elicited peritoneal MØ were col-
lected at different times and tested for the presence of MR. cMR
and sMR were detected in protein lysates and conditioned
media, respectively (Fig. 1). cMR was the expected size (175
kDa) (3) and, as described previously (22), its accumulation was
up-regulated by IL-4. This effect was further increased in the
presence of FCS. sMR was detected after 24 h of culture and
accumulated in the conditioned media. Only one form of sMR
with slightly faster mobility than cMR was found. No release of
another MØ-specific integral membrane protein, F4/80, was
detected under these conditions (data not shown). sMR was not
recognized by an antibody specific for the cytoplasmic tail of the
MR (Fig. 2). This result suggests that sMR lacks this domain
and could be produced by proteolytic cleavage of the cell-asso-
ciated form of the receptor. sMR was stable, was not affected by
freezing and thawing, and could be stored at 220 °C for long
periods of time.
sMR Ligand Binding Properties—The binding properties of
sMR were characterized using a semiquantitative ligand Bind-
ing assay. sMR bound specifically to p-aminophenyl a-D-man-
nose-agarose, and this interaction was inhibited by EDTA.
Binding of sMR to the beads was inhibited by millimolar con-
centrations of D-mannose and L-fucose but not by D-galactose
(Fig. 3), in good agreement with the published specificity for
MR: D-mannose 5 L-fucose . D-galactose (15). As expected,
mannan and mannose-BSA were much more potent inhibitors
of sMR binding, with approximate IC50 values of 10 nM and 3
mg/ml, respectively (not shown). The same type of assay was
used to test the ability of sMR to bind natural particulate
antigens, i.e. heat-killed C. albicans or zymosan (Fig. 4). In
both cases the interaction was inhibited by D-mannose and
L-fucose (10 mM) but not by 10 mM D-galactose.
Regulation of sMR Production—MR synthesis is regulated
by MØ maturation, LPS (3), and cytokines. It is inhibited by
IFN-g (6) and up-regulated by IL-4 and -13 (21, 22). To char-
acterize in more detail the relationship between cMR and sMR
production, pulse-chase experiments were performed under dif-
ferent culture conditions, as described under “Experimental
Procedures.” Fig. 5 shows the effect of IL-4, IFN-g, and LPS on
cMR and sMR synthesis. After the pulse, two bands corre-
sponding to the precursor and mature forms of cMR (3) were
FIG. 1. A soluble form of the MR detected in supernatants from
Bio-Gel-elicited peritoneal MØ. Western blot analysis of cell lysates
(15 mg, upper panel) and conditioned media (lower panel) from Bio-Gel-
elicited MØ cultured in the absence or presence of FCS and/or IL-4 and
collected at days 0 (d0), 1 (d1), and 3 (d3) with a polyclonal antibody
against murine MR is shown. The asterisk indicates cultures in which
medium was changed on day 1.
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recognized by the anti-MR polyclonal antibody in cell lysates.
cMR synthesis was increased by IL-4 and decreased by LPS. No
obvious difference in the rate of synthesis was observed in the
case of IFN-g under these conditions. sMR could already be
detected in supernatants collected after a 2-h pulse in samples
treated with IL-4. Analysis of samples collected after the 3-h
chase showed the disappearance of the precursor form in the
cell lysates (probably chased into the mature form of cMR) and
the presence of sMR in the conditioned media from IL-4-treated
cells. IFN-g and LPS treatments seemed to reduce the half-life
of the cellular receptor, although the reduction in the intensity
of the bands could be because of the production of sMR, which
is undetectable at this time point. After the 8-h chase, sMR
could be detected in supernatants from control and IL-4- and
IFN-g-treated cells in amounts proportional to their rate of
synthesis. This finding indicated that the production of sMR
was constitutive and that the amount of sMR correlated with
the amount of cMR present in the cell. No differences in sMR
production were observed when IL-4 or IFN-g was added only
during the chase period (data not shown).
sMR Production Is Blocked by an Inhibitor of Matrix Metal-
loproteinases—As a first step toward characterization of the
cleavage event that generates sMR, peritoneal MØs were
pulsed with Tran35S-label followed by a chase in the presence
of a variety of protease inhibitors. As shown in Fig. 6, the
protease inhibitor BB 2116, a synthetic hydroxamic acid-based
inhibitor of matrix metalloproteases (26, 27), blocked produc-
tion of sMR in a concentration-dependent manner, with an IC50
of approximately 3 mg/ml. The decrease in sMR production was
unlikely to be caused by cell toxicity, because even at the
highest concentration tested, 50 mg/ml, cell viability was
greater than 95% by trypan blue staining. Other protease in-
hibitors tested were either ineffective or had modest and/or
variable effects (Fig. 6).
sMR Is Present in Mouse Serum—The detection of sMR in
conditioned media from cultured peritoneal MØ might be con-
sidered an artifact of this in vitro system. For that reason, the
presence of sMR in normal mouse serum was examined. A
protein that reacted with the anti-MR polyclonal antibody and
comigrated with sMR from MØ-conditioned media could be
detected using just 0.5 ml of mouse serum (data not shown).
This protein displayed sugar binding activity similar to the
activity described above for sMR (Fig. 7). These findings indi-
cate that sMR production occurs in vivo and that sMR is a
component of normal mouse serum. sMR levels in mouse serum
were not affected by Mycobacterium bovis bacillus Calmette-
Gue´rin or C. albicans infection, or by intraperitoneal treatment
with LPS, zymosan, or heat-killed C. albicans (data not shown).
DISCUSSION
In this study we demonstrate that there is a functional
soluble form of murine MR produced by MØ in vitro and pres-
ent in mouse serum. sMR migrated faster than cMR on SDS-
PAGE, presumably because of cleavage of the transmembrane
domain and cytoplasmic tail (see Fig. 2), and was produced by
cleavage of a pre-existing full-size cMR (Fig. 5). No sMR was
found in cell lysates. sMR could be stored at 220 °C for long
periods of time with no obvious change in mobility on SDS-
PAGE or in sugar binding ability. The production of a single
species of sMR is consistent with specific cleavage of cMR to
produce a functional soluble form. sMR was able to interact
with carbohydrates in a mannose- and fucose-dependent man-
ner (Figs. 3 and 4). These results agreed with previous studies
FIG. 2. An antibody specific for the cytoplasmic tail of the MR
does not recognize sMR. Cell lysate (7 mg, C) and concentrated
supernatant (1, 2.5, and 5 ml, S) from Bio-Gel-elicited MØ cultured in
RPMI-2% FCS in the presence of IL-4 (10 ng/ml) were analyzed by
Western blot with polyclonal antibodies raised against purified murine
MR (a-MR) or a synthetic peptide with part of the COOH-terminal
sequence of murine MR, as described under “Experimental Procedures”
(a-MR-COOH). The control panel shows results obtained with preim-
mune antibody. a-MR-COOH failed to recognize the soluble form of the
MR found in the supernatant.
FIG. 3. Carbohydrate binding activity of sMR. Concentrated su-
pernatant from MØ cultured in the presence of 2% FCS and IL-4 was
incubated with p-aminophenyl a-D-mannosyl-agarose in the absence
(control) or presence of EDTA (10 mM), D-mannose, L-fucose, or D-
galactose (0.01, 0.1, 1, or 10 mM), as described under “Experimental
Procedures.” Bound material was analyzed by Western blot using the
anti-MR polyclonal antibody as described above. sMR bound specifically
to mannosylated agarose beads in a Ca21-dependent manner, and this
interaction could be inhibited by D-mannose and L-fucose but not by
D-galactose.
FIG. 4. Binding of sMR to heat-killed Candida albicans and
zymosan. Concentrated supernatant from MØ cultured in the presence
of 2% FCS and IL-4 was incubated with p-aminophenyl a-D-mannose-
agarose (Man-O), 2 3 107 zymosan particles, or 2 3 107 heat-killed C.
albicans in the absence (2) or presence of D-mannose (10 mM), L-fucose
(10 mM), or D-galactose (10 mM), as described under “Experimental
Procedures.” Bound material was analyzed by Western blot using the
anti-MR polyclonal antibody. sMR bound to heat-killed C. albicans and
zymosan in a Ca21- and mannose and fucose-dependent manner.
FIG. 5. Effect of IL-4, IFN-g, and LPS on MR synthesis and sMR
release. Bio-Gel-elicited MØ, cultured overnight in the absence (Con)
or presence of IL-4, IFN-g or LPS, were pulsed with 35S for 2 h (pulse)
or pulsed for 2 h and then chased for 3 or 8 h, as described under
“Experimental Procedures.” cMR and sMR were immunoprecipitated
from cell lysates (C) and conditioned media (S), respectively, using an
anti-MR polyclonal antibody, resolved by SDS-PAGE, and visualized by
fluorography. The amount of immunoprecipitated MR was quantified
by PhosphorImager analysis.
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of sugar specificity of purified human MR (15) or complete and
truncated forms of the human receptor expressed in vitro (18).
The assays developed here allow the direct study of sMR inter-
actions with a wide range of pathogens in a cell-free system. We
showed that sMR interacted with heat-killed C. albicans and
zymosan (prepared from the S. cerevisiae cell wall) in the same
way as it bound p-aminophenyl a-D-mannosyl-agarose. Phago-
cytosis of unopsonized C. albicans by MØ has been shown to be
mediated, to a considerable extent, by the MR; mannan and
mannose-BSA inhibited 80% of C. albicans uptake by human
monocyte-derived MØ (25) and murine peritoneal MØ.2
The inhibition of sMR production by the matrix metallopro-
tease inhibitor BB 2116 strongly suggests a role for a metallo-
protease in the release of sMR from the membrane. The matrix
metalloproteases are a large family of extracellular zinc pro-
teases, at least 18 distinct members of which have been discov-
ered (28). A growing number of integral membrane proteins in
the immune system have been shown to be released from cells
by the action of metalloproteases, including tumor necrosis
factor a (TNFa) (26, 29), TNFa receptor (30), L-selectin (31),
and Fas ligand (32). TNFa, perhaps the most well understood
of this group, is released from MØ by the action of TNFa-
converting enzyme (33, 34) and/or ADAM10 (35, 36), both mem-
bers of the ADAM family of metalloproteases. At least 17 mem-
bers of this family, which feature metalloprotease and
disintegrin domains, have now been identified (28). Because
BB 2116 can also inhibit TNFa release (26), the sMR releasing
activity may be either a matrix metalloprotease or an ADAM
family metalloprotease. Further studies with specific inhibitors
should help to answer this question.
Unlike cMR synthesis, sMR production per se was not regu-
lated by cytokines (IFN-g and IL-4), but because the amount of
sMR in conditioned media of cytokine-treated cells was directly
related to the amount of cMR present in the cell, the total
amount of sMR was effectively cytokine-regulated and followed
the pattern described for cMR (6, 22). It should be noted that
IFN-g- (Fig. 5) and phorbol 12-myristate 13-acetate-induced
down-regulation of MR (data not shown) could not be explained
by increased cMR processing. Therefore, at least in these cases,
sMR production was not a mechanism of down-modulation of
MR activity as described for other leukocyte surface molecules
(37, 38).
One of the best characterized lectins in serum is the mannose
binding protein (MBP) (39), a C-type lectin with specificity for
mannose and N-acetylglucosamine. Major differences between
the MBP and sMR are suggestive of complementary roles in
their interaction with mannosylated antigens. (i) In the case of
MBP, 32-kDa monomers, each containing one CRD, form clus-
ters to achieve high affinity binding, but a single sMR molecule
binds to sugar with high affinity because of the presence of
eight CRDs in tandem (19). Indeed, just CRDs 4–8 are suffi-
cient for this interaction (18, 19). sMR might be forming com-
plexes in serum, but they would not be necessary for its binding
to glycoconjugates. (ii) MBP, a moderate acute-phase reactant,
is increased, for example, after surgery or malarial infection.
No modulation of sMR levels in serum has yet been found. (iii)
MBP can activate the classical pathway of complement and act
as an opsonin; MBP-pathogen complexes could be cleared
through the interaction of the collagen region of MBP with
collectin receptors expressed by most phagocytic cells. Li-
gand(s) for the cysteine-rich domain of the MR has been found
on marginal zone metallophilic MØ in spleen, subcapsular si-
nus MØ in lymph nodes, germinal centers (specific cell type
unknown), and a population of cells with dendritic morphology
that migrate into the follicles during an immune response2 R. Ka´poszta, unpublished results.
FIG. 6. sMR release is specifically blocked by an inhibitor of
matrix metalloproteases. A, Bio-Gel-elicited MØs, cultured over-
night in the presence of IL-4, were pulsed with 35S for 3 h (pulse) or
pulsed for 3 h and then chased for 16 h in the presence of protease
inhibitors, as described under “Experimental Procedures.” cMR and
sMR were immunoprecipitated from cell lysates (C) and conditioned
media (S), respectively, using an anti-MR polyclonal antibody, resolved
by SDS-PAGE, and visualized by fluorography. Inhibitor concentra-
tions were: BB 2116, 1, 10, and 50 mg/ml; E-64, 1 mg/ml; a2-macroglob-
ulin (a2M), 0.4 unit/ml; pepstatin (Pep), 1 mg/ml. B, concentration-de-
pendent inhibition of sMR release by BB 2116. Immunoprecipitated
sMR was resolved by SDS-PAGE and quantified by PhosphorImager
analysis and expressed as percent released in the absence of inhibitor.
FIG. 7. sMR is present in normal mouse serum. 50 ml of normal
mouse serum were incubated with p-aminophenyl a-D-mannosyl-agar-
ose (Man-O) in the absence or presence of 10 mM EDTA, 10 mM D-
mannose, or 10 mM D-galactose as described under “Experimental Pro-
cedures.” Bound material was analyzed by Western blot using the
anti-MR polyclonal antibody as described. p-Aminophenyl a-D-galacto-
syl-agarose (Gal-O) was used as a negative control. C, Western blot
analysis of cell lysate from Bio-Gel-elicited MØ; S, Western blot anal-
ysis of supernatant from Bio-Gel-elicited MØ.
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(CR-Fc1 cells) (23). sMR could interact with whole infectious
agents (i.e. C. albicans) or cleavage products released after
phagocytosis through the CRDs and with ligand(s) present on
the cells described previously through the cysteine-rich do-
main. In this way, sMR-bound antigens would not be targeted
for clearance but delivered, in their native form, to the CR-Fc1
cells surrounding the white pulp of the spleen or follicular
regions in lymph nodes. Accordingly, sMR levels were in-
creased in the presence of IL-4, a Th2 cytokine. We propose
that mannosylated antigen opsonized by the MBP could also be
targeted to these areas because of the presence of complement
receptors on dendritic cells and follicular dendritic cells. Com-
plement activity is necessary for the follicular localization of
T-independent type-2 antigen (40), and in secondary lymphoid
follicles, trapping of immune complexes by follicular dendritic
cells was mediated by complement receptors 1 and 2 (41).
Recently, a liver-specific form of the MR was identified as
responsible for the clearance of the glycoprotein hormone
lutropin through the recognition of the sulfated carbohydrate
structure SO4-4-GalNacb1,4Glc-NAcb1,2Mana (42, 43). The
binding site has been localized to the cysteine-rich domain of
the receptor (44). Therefore, the possible competition of
lutropin with the cysteine-rich domain ligands found in lymph-
oid organs should be considered. The tissue specificity of this
recognition and the heterogeneity in binding properties found
for recombinant MR expressed in Chinese hamster ovary cells
(43) suggest that post-translational modifications could alter
the binding properties of the cysteine-rich domain and deter-
mine the ability of MR to bind lutropin. In the case of sMR, no
data are yet available regarding its cellular origin in vivo (e.g.
hepatic endothelium versus MØ) or its ability to interact with
lutropin.
The MR has been implicated in the uptake of mannosylated
antigens and their delivery to different intracellular compart-
ments for their presentation in association with major histo-
compatibility complex class II in the case of peptides (4) or CD1
in the case of nonpeptides (16). We propose a possible third
mechanism of presentation of glycoconjugates: in their native
form bound to sMR and attached to the cysteine-rich domain
ligand(s) expressed by specialized antigen-bearing cells.
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